Decreased human paraoxonase-1 activity in patients with Sjögren's syndrome

International Immunology

Volumn 22, Issue 7, 2010, Pages 605-609

  Szántó, Antónia ^a   Harangi, Mariann ^a   Seres, Ildikó ^a   Paragh, György ^a   Zeher, Margit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Autoimmunity; Cardiovascular risk; Paraoxonase phenotype

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; LA ANTIBODY; RO ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME DEFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SJOEGREN SYNDROME; SPECTROPHOTOMETRY;

ARYLDIALKYLPHOSPHATASE; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; SJOGREN'S SYNDROME;

EID: 77954291930     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxq045     Document Type: Article

References (25)

1. Shoenfeld, Y., Gerli, R., Doria, A. et al. 2005. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337.
2. Vaudo, G., Bocci, E. B., Shoenfeld, Y. et al. 2005. Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum. 52:3890.
3. Lodde, B. M., Sankar, V., Kok, M. R. et al. 2006. Serum lipid levels in Sjogren's syndrome. Rheumatology 45:481.
4. Gerli, R., Bartoloni Bocci, E., Vaudo, G., Marchesi, S., Vitali, C. and Shoenfeld, Y. 2006. Traditional cardiovascular risk factors in primary Sjögren's syndrome-role of dyslipidaemia. Rheumatology (Oxford) 45:1580.
5. Primo-Parmo, S. L., Sorenson, R. C., Teiber, J. and La Du, B. N. 1996. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498.
6. Kelso, G. J., Stuart, W. D., Richter, R. J., Furlong, C. E., Jordan-Starck, T. C. and Harmony, J. A. 1994. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33:832.
7. La Du, B. N., Adkins, S., Kuo, C. L. and Lipsig, D. 1993. Studies on human serum paraoxonase/arylesterase. Chem. Biol. Interact. 7:25.
8. Mackness, M. I., Arrol, S., Abbott, C. A. and Durrington, P. N. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129.
9. Mackness, B., Mackness, M. I., Arrol, S., Turkie, W. and Durrington, P. N. 1997. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol. 122:265.
10. Leviev, I. and James, R. W. 2000. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20:516.
11. Eckerson, H., Wyte, C. and La Du, B. N. 1983. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35:1126.
12. Kerekes, G., Szekanecz, Z., Dér, H. et al. 2008. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol. 35:398.
13. Bodolay, E., Seres, I., Szodoray, P. et al. 2008. Evaluation of paraoxonase activity in patients with mixed connective tissue disease. J. Rheumatol. 35:237.
14. Kiss, E., Seres, I., Tarr, T., Kocsis, Z., Szegedi, G. and Paragh, G. 2007. Reduced paraoxonase1 activity is a risk for atherosclerosis in patients with systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1108:83.
15. Vitali, C., Bombardieri, S., Jonsson, R. et al. 2002. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61:554.
16. Paragh, G., Seres, I., Balogh, Z. et al. 1998. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 80:166.
17. La Du, B. N. and Eckerson, H. W. 1984. The polymorphic paraoxonase/arylesterase isozymes of human serum. Fed. Proc. 43:2338.
18. Hahn, B. H., Grossman, J., Ansell, B. J., Skaggs, B. J. and McMahon, M. 2008. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res. Ther. 10:213.
19. Salmon, J. E. and Roman, M. J. 2008. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am. J. Med. 121:S3.
20. Szekanecz, Z., Kerekes, G., Dér, H. et al. 2007. Accelerated atherosclerosis in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1108:349.
21. Gerli, R., Bocci, E. B., Vaudo, G., Marchesi, S., Vitali, C. and Shoenfeld, Y. 2006. Traditional cardiovascular risk factors in primary Sjogren's syndrome-role of dyslipidemia. Rheumatology 45:1580.
22. Turesson, C., McClelland, R. L., Christianson, T. J. and Matteson, E. L. 2007. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66:70.
23. McMahon, M., Grossman, J., FitzGerald, J. et al. 2006. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54:2541.
24. Harangi, M., Seres, I., Magyar, M. T. et al. 2008. Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease. Cerebrovasc. Dis. 25:122.
25. Loftus, I. M., Naylor, A. R., Goodall, S. et al. 2000. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31:40.